Abstract
Evidence for an association between ABO blood type and epithelial ovarian cancer (EOC) survival has so far been limited and conflictive. This study applied a retrospective cohort and included 627 EOC patients diagnosed at Shengjing Hospital of China Medical University between 2011 and 2015. Adjusted hazard ratios (HRs) and 95% confidence intervals (CIs) between the ABO blood type and progression-free survival (PFS) and overall survival (OS) of EOC patients were assessed using multivariable Cox proportional regression models. The median follow-up duration was 2.97 years (inter-quartile range from 2.11 to 4.13 years). The recurrence and mortality rates were 41.5% (260/627) and 37.0% (232/627), respectively. Possessing a comorbidity, residual disease, ascites, and advanced FIGO stage (III/IV) were associated with worse PFS and OS of EOC patients. The distribution of blood types O, A, B, and AB among patients was 27.4%, 31.3%, 33.2%, and 8.1%, respectively. Compared with blood type O, none of the blood types (A, B, and AB) were significantly associated with PFS or OS. However, in the stratified analyses, we found borderline significant results for PFS with blood type AB (HR = 0.56, 95% CI = 0.31-1.01) compared with blood type O. No significant differences were observed for blood type A when compared with all non-A blood type cases. This study does not support an association between ABO blood type and EOC survival. Further prospective cohort studies are warranted to confirm our findings.